TD2 Precision Oncology

TD2 Precision Oncology is a full-service oncology CRO that differentiates itself through deep therapeutic expertise and an integrated ecosystem designed to accelerate cancer drug development. The company serves biotech and pharmaceutical clients with a comprehensive suite spanning preclinical research (featuring over 400 cancer models), clinical trial design and execution, and strategic regulatory navigation. TD2 demonstrates innovation through its focus on complex modalities like radiopharmaceuticals, ADCs, and cell therapies, and actively contributes to the scientific community via publications and strategic collaborations.

Integrated oncology-focused service ecosystem encompassing preclinical models (400+ cancer models), clinical trial management, regulatory strategy, and advanced flow cytometry analytics.

TD2 competes in the oncology CRO segment against large, diversified global CROs (e.g., IQVIA, LabCorp) and smaller specialized oncology CROs. Its differentiation lies in its deep, exclusive focus on oncology, an integrated end-to-end service offering, and recognized expertise in novel modalities like radiopharmaceuticals and cell therapies.